Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upifitamab rilsodotin (XMT-1536) Dose Expansion in Solid Tumors
NCT06517485Phase 1Completed
- Sponsor
- Mersana Therapeutics
- Start
- Jul 2019
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of upifitamab rilsodotin in ovarian cancer and Non-small cell lung cancer adenocarcinoma (NSCLC) (2 cohorts), sponsored by Mersana Therapeutics. Primary endpoint: Safety and Tolerability. Started Jul 2019; status: completed.
02
Drugs
upifitamab rilsodotin
03
Conditions
ovarian cancerNon-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on NCT06517485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06517485.